Special Issue "Hormone Therapy"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 June 2012)
Dr. John Eden
Department of Reproductive Endocrinology, The University of New South Wiles, Sydney, Australia
Interests: menopause after breast cancer; polycystic ovary syndrome (PCOS); osteoporosis; biofilms; hormone replacement therapy as well as herbal medicine
Some years ago HT was being touted as a treatment for most if not all menopausal women to treat symptoms such as hot flushes as well as a preventive agent for heart disease and osteoporosis. However, since the first publication of the results of the Women's Health Initiative (WHI) in July 2002, HT usage has declined substantially. Much of the female population is now fearful that HT usage may increase their risk of breast cancer. Around a quarter of women will have severe menopausal symptoms as they pass through the menopause transition and some will have symptoms for the rest of their lives. How safe is HRT? How should we manage women who have severe menopausal flushing for years? Which is the best method for managing genitourinary symptoms? These are some of the questions being addressed this this issue.
Dr. John Eden
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- hormone therapy
- hormone replacement therapy
- women's health initiative
- nurse's health study
- million women
- studytestosterone (replacement)
- androgen (replacement)
Review: Hormesis and Female Sex Hormones
Pharmaceuticals 2011, 4(5), 726-740; doi:10.3390/ph4050726
Received: 12 April 2011; in revised form: 5 May 2011 / Accepted: 10 May 2011 / Published: 16 May 2011| Download PDF Full-text (205 KB) | Download XML Full-text
Review: The Influence of Estrogens on the Biological and Therapeutic Actions of Growth Hormone in the Liver
Pharmaceuticals 2012, 5(7), 758-778; doi:10.3390/ph5070758
Received: 4 June 2012; in revised form: 9 July 2012 / Accepted: 12 July 2012 / Published: 19 July 2012| Download PDF Full-text (763 KB) | Download XML Full-text
Pharmaceuticals 2012, 5(9), 899-924; doi:10.3390/ph5090899
Received: 2 July 2012; in revised form: 18 August 2012 / Accepted: 24 August 2012 / Published: 4 September 2012| Download PDF Full-text (256 KB) | Download XML Full-text
Pharmaceuticals 2012, 5(10), 1120-1127; doi:10.3390/ph5101120
Received: 8 July 2012; in revised form: 4 October 2012 / Accepted: 15 October 2012 / Published: 22 October 2012| Download PDF Full-text (182 KB) | Download XML Full-text
Last update: 18 May 2012